#ESMO26 🔬 VOLGA (Phase 3)
Peri-op durvalumab ± tremelimumab + neoadjuvant EV ×3 vs upfront cystectomy in cisplatin-ineligible MIBC
D+EV vs control
✅ EFS HR 0.51 | 2-yr 64% vs 45%
✅ OS HR 0.58 | 2-yr 78% vs 69%
✅ pCR 40% vs 8%
D+T+EV vs control
✅ EFS HR 0.61 | 2-yr 60% vs 45%
❌ OS HR 0.77 (NS)
⚠️ G3–4 AEs: 64% / 70% / 44%
⚠️ imAEs: 33% / 48% / 3%
💡 Treme adds toxicity, no clear gain. D+EV is a new option for cis-ineligible MIBC.
@myESMO @OncoAlert